SCHEMBL6920475

SCHEMBL6920475

CC(C)c1ccc(C(=O)O)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 13/20 0.53
P4HA1 P13674 1/20 0.53
MIF P14174 1/20 0.53
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 2/20 0.52
L3MBTL1 Q9Y468 3/20 0.49
MAPK1 P28482 1/20 0.49
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
HIF1A Q16665 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
THPO P40225 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30181544 1.00 P4HTM (0.53) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL27837540 0.86 P4HTM (0.52) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL2627835 0.85 EGLN1 (0.56) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL19441050 0.85 P4HTM (0.50) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL14358092 0.85 KDM4E (0.53) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL25523204 0.85 P4HTM (0.50) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL8150961 0.84 NPC1 (0.44) P4HTMP4HA1MIFKDM4EALDH1A1
Hydrochloric Acid SCHEMBL18740089 0.83 P4HTM (0.49) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL6652918 0.83 P4HTM (0.49) P4HTMP4HA1MIFKDM4EALDH1A1
Hydrochloric Acid SCHEMBL20539069 0.83 P4HTM (0.49) P4HTMP4HA1MIFKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145259-A2 EP2 ANTAGONIST COMPOUNDS RESERVOIR NEUROSCIENCE, INC. (US) 2024-07-04 WO disclosed
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed
WO-2022272060-A1 EP2 ANTAGONIST COMPOUNDS RESERVOIR NEUROSCIENCE, INC. (US) 2022-12-29 WO disclosed
US-20220411432-A1 MDM2 PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2022-12-29 US disclosed
US-11192898-B2 MDM2 protein degraders THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-12-07 US disclosed
US-20210323970-A1 METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-21 US disclosed
CN-113329996-A Compounds and methods for treating hedgehog pathway related disorders 苏州麦迪耐斯医药科技有限公司 2021-08-31 CN disclosed
US-10865216-B2 Tricyclic Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-15 US disclosed
US-10851111-B2 Method for producing a spirooxindole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-12-01 US disclosed
US-20100048557-A1 Triazolopyridine JAK Inhibitor Compounds and Methods GENENTECH, INC. 2010-02-25 US disclosed
US-20100035875-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. 2010-02-11 US disclosed
US-20090270412-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2009-10-29 US disclosed
US-20090270412-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2009-10-29 US disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
US-20090186830-A1 MACROCYCLES AND THEIR USES NOVARTIS AG (CH) 2009-07-23 US disclosed
US-20080146811-A1 Compounds and Methods For Treatment of Thrombosis DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC 2008-06-19 US disclosed
WO-2006012504-A2 COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS DAIAMED, INC. (US) 2006-02-02 WO disclosed
WO-1984004302-A1 SUBSTITUTED PICOLINIC ACIDS, PROCESSES FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM BYK GULDEN LOMBERG CHEM FAB (DE) 1984-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192898-B2 MDM2 protein degraders MDM2, TP53, TP53BP1 P4HTM 3169/4885P4HA1 936/4885MIF 1175/4885
US-20100048557-A1 Triazolopyridine JAK Inhibitor Compounds and Methods JAK2, JAK1, JAK3 P4HTM 1591/4885P4HA1 1187/4885MIF 3624/4885
US-20080146811-A1 Compounds and Methods For Treatment of Thrombosis F2, SERPINC1, PLAT P4HTM 375/4885P4HA1 246/4885MIF 4540/4885
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF HDAC6, PSMG3, PSMB2 P4HTM 2516/4885P4HA1 1455/4885MIF 4052/4885
US-20090270412-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C P4HTM 563/4885P4HA1 1223/4885MIF 3485/4885
US-20220411432-A1 MDM2 PROTEIN DEGRADERS MDM2, TP53, TP53BP1 P4HTM 3169/4885P4HA1 936/4885MIF 1175/4885
US-20090186830-A1 MACROCYCLES AND THEIR USES CYP11B2, OAT, CYP27A1 P4HTM 1684/4885P4HA1 2402/4885MIF 1517/4885
US-20210323970-A1 METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE MDM2, TP53, RB1 P4HTM 4214/4885P4HA1 3133/4885MIF 1477/4885
US-10851111-B2 Method for producing a spirooxindole derivative MDM2, TP53, RB1 P4HTM 4214/4885P4HA1 3133/4885MIF 1477/4885
US-20090239854-A1 Tetracyclic compounds HTR2C, HTR3D, HTR5A P4HTM 1005/4885P4HA1 1989/4885MIF 1521/4885
US-20100035875-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 P4HTM 1591/4885P4HA1 1187/4885MIF 3624/4885
US-10865216-B2 Tricyclic Gyrase inhibitors TOP1, TOP2A, TOP2B P4HTM 3789/4885P4HA1 2121/4885MIF 3475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.